Targeted radionuclide therapy for metastatic lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I study evaluates the safety and efficacy of a theranostic pair, [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G, in patients with metastatic non-small cell lung cancer (NSCLC). The study utilizes [68Ga]Ga DOTA-5G PET/CT imaging to identify patients who are most likely to respond to the therapy. Up to 40 patients will be enrolled over 36 months, focusing on those with documented disease progression after prior treatments. The goal is to assess both the safety of the therapy and the potential therapeutic response from a single dose.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\[68Ga\]Ga DOTA-5G PET/CT Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent document.
2. Age 18 or more years
3. Pathologically confirmed NSCLC with metastatic disease and measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \> 1 cm or lymph node \> 1.5 cm in short axis)
4. Participant must have documented tumor progression for metastatic disease during or following at least one prior FDA approved systemic regimen as established by diagnostic imaging.
5. Available archival tumor tissue (excisional, core, or FNA is acceptable). Tissue from a metastatic site is preferred when available.
6. Eastern Cooperative Oncology Group Performance Status ≤ 2
7. Participant must have completed prior systemic therapy at least 2 weeks (washout period) prior to \[68Ga\]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to Grade 1 or baseline.
8. Hematologic parameters defined as:

   Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 8 g/dL
9. Blood chemistry levels defined as:

   AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN) Total bilirubin ≤ 2 times ULN Creatinine ≤ 2 times ULN
10. Anticipated life expectancy ≥ 3 months
11. Able to remain motionless for up to 30-60 minutes per scan

\[177Lu\]Lu DOTA-ABM-5G therapy Inclusion Criteria:

1. Completion of entry into \[68Ga\]Ga DOTA-5G PET study and completion of scan
2. The presence of at least one measurable disease by \[68Ga\]Ga DOTA-5G PET/CT (SUVmax\>2-fold above normal bone, brain, lung or liver and identified on standard of care diagnostic imaging) Patients with a history of brain metastases and or any clinical concern for brain metastases will be evaluated with brain MRI as per standard of care for patients with metastatic NSCLC.

Exclusion Criteria:

\[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G therapy Exclusion Criteria:

1. Participants with Class 3 or 4 NYHA Congestive Heart Failure
2. Clinically significant bleeding within two weeks prior to trial. entry (e.g. gastrointestinal bleeding, intracranial bleeding)
3. Pregnant or lactating women
4. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of a central venous access, percutaneous feeding tube, or biopsy) within 28 days prior to study day 1 or anticipated surgery within the subsequent 6 weeks
5. Has an additional active malignancy requiring therapy within the past 2 years (other than early stage, surgically managed basal and squamous skin cancer and in situ malignancies of the breast and cervix)
6. Active, uncontrolled bacterial, viral, or fungal infection(s) despite systemic therapy
7. Psychiatric illness/social situations that would interfere with compliance with study requirements
8. Cannot undergo PET/CT or SPECT/CT scanning because of weight limits (350 lbs.)
9. Known interstitial lung disease or pre-existing pulmonary fibrosis
10. INR \>2.0: PTT\>15 seconds above ULN

Where it's running

• The University of California Davis Comprehensive Cancer Center
  Sacramento, California, United States Recruiting

Study contacts

• Principal investigator: Julie L Sutcliffe, PhD — University of California, Davis
• Study coordinator: Julie L Sutcliffe, Phd
• Email: jlsutcliffe@ucdavis.edu
• Phone: 9167345536

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing chemo‑immunotherapy options for metastatic NSCLC with PD‑L1 <50%

  This project will see if two common first‑line chemo‑immunotherapy approaches give different survival and quality‑of‑life results for adults with metastatic NSCLC whose tumors have PD‑L1 under 50%.

  Recruiting at 2 sites Gazi University · Ankara and 1 other locations · NCT07394062

• Optimizing Adaptive Deep Brain Stimulation for Parkinson's Disease

  This study tests whether using ongoing brain signals gathered during daily life can improve adaptive deep brain stimulation for people with Parkinson's who have motor fluctuations.

  Recruiting University of California, Davis · Davis, California · NCT07798271

• How movement and nervous system function relate after stroke

  This study tests whether measures of movement efficiency and nerve function relate to outcomes in adults who had a stroke.

  Recruiting University of California, Davis · Sacramento, California · NCT07737873

• Support for caregivers of people with heart disease to reduce stress

  This study tests whether the Confident Caregiver program can help family caregivers of people with cardiovascular disease feel less burdened and stressed, with sessions delivered virtually.

  Recruiting University of California, Davis · Sacramento, California · NCT07717723

• Normal lymphatic anatomy in breast cancer patients using ultra-high frequency ultrasound and ICG

  This study tests whether ultra-high frequency ultrasound plus indocyanine green dye can map normal lymphatic channels in breast cancer patients undergoing axillary procedures.

  Recruiting University of California, Davis · Sacramento, California · NCT07677839

• Rhythmic cues to help walking after spinal cord injury

  This pilot test will see if a wearable rhythm device (MedRhythms) can help adults with motor incomplete spinal cord injury walk more steadily and comfortably.

  Recruiting University of California, Davis · Sacramento, California · NCT07674927

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.